Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-09-23 pm EDT
166.72 USD   +0.32%
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/22Johnson & Johnson - Diversifying Our Health Workforce through the Impact of AIM
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Pacific at Duke-NUS to Advance Dengue Research

06/21/2022 EDT

Johnson & Johnson announced the launch of the new J&J Satellite Center for Global Health Discovery (Satellite Center) at Singapore's Duke-NUS Medical School, jointly established by Duke University and the National University of Singapore (NUS) as a graduate-entry medical school and research powerhouse. As the first of the J&J Centers for Global Health Discovery (J&J Centers) in the Asia-Pacific region, the Satellite Center at Duke-NUS aims to help drive new solutions to address flaviviruses, which disproportionately impact communities across the region, by bringing together the talent and expertise of the world's healthcare company with that of a leading academic institution. The J&J Centers for Global Health Discovery (J&J Centers) are a pillar of Johnson & Johnson's efforts to advance early-stage, breakthrough science where research is needed most and health challenges are most acute.

The latest Satellite Center builds on a longstanding collaboration between the Janssen Pharmaceutical Companies of Johnson & Johnson and Duke-NUS and marks the latest effort of the SingHealth Duke-NUS Academic Medical Centre to develop a collaborative Discovery District on its Campus to drive bench-to-bedside innovations. The collaboration will unite expertise from across the scientific community in the Asia-Pacific region to further cultivate Singapore as a hub of discovery research, while advancing R&D to address the unmet medical need of flaviviruses. Research at the Satellite Center at Duke-NUS will be led by Professor Subhash Vasudevan, Ph.D., Duke-NUS' EID Program, and Olivia Goethals, Ph.D., Principal Scientist, Global Public Health R&D, Janssen Pharmaceutica NV.


© S&P Capital IQ 2022
All news about JOHNSON & JOHNSON
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/22Johnson & Johnson - Diversifying Our Health Workforce through the Impact of AIM
AQ
09/22Over 200 Inmates, Prison Officers Vaccinated Against Covid-19
AQ
09/21J&J's talc Texas two-step called out by victims
AQ
09/20No, Covid Vaccines Don't Cause Body to Produce Toxic Spike Proteins That Cause Cancer
AQ
09/20Johnson & Johnson Sets Up New R&D Facility in San Francisco Bay Area
MT
09/20Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco..
BU
09/20Johnson & Johnson Opens New R&D Facility in San Francisco Bay Area
DJ
09/19JOHNSON & JOHNSON : Debuts a Groundbreaking R&D Facility in the San Francisco Bay Area
PU
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 525 M - -
Net income 2022 22 023 M - -
Net cash 2022 9 791 M - -
P/E ratio 2022 20,4x
Yield 2022 2,62%
Capitalization 438 B 438 B -
EV / Sales 2022 4,49x
EV / Sales 2023 4,20x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 166,72 $
Average target price 185,07 $
Spread / Average Target 11,0%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-2.54%438 337
ELI LILLY AND COMPANY12.54%295 941
ROCHE HOLDING AG-18.41%259 291
ABBVIE INC.5.66%252 944
PFIZER, INC.-25.35%247 392
NOVO NORDISK A/S1.95%221 838